Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Simon Property Group Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while Simon Property Group Inc trades at $200.17 (market cap $64.92B). The key difference: Simon Property Group Inc is far larger — about 22.7× Dyne Therapeutics Inc. Common Stock's market cap, and Simon Property Group Inc pays a 4.44% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Simon Property Group Inc for 100 Days on average.
| DYN | SPG | |
|---|---|---|
Market Cap | $2.86B | $64.92B |
Volume | 3,341,579 | 1,919,136 |
Sector | Health | Real Estate |
52-Week High | $26.78 | $236.70 |
52-Week Low | $14.60 | $173.35 |
Typical Hold Time | 0 Days | 100 Days |
Enterprise Value | $2.18B | $93.37B |
Dividend Yield | — | 4.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
SPG trades at $198.70, down 1.35% with bearish technical signals from moving averages and ADX indicators. The REIT maintains strong fundamentals with Q4 2025 EPS beating expectations at $9.35 versus $1.90, though Q2 2026 missed at $1.49 versus $1.64. Recent news highlights strong leasing demand and a new $800 million debt issuance, while directors made small stock purchases in late September 2026.
SPG presents a mixed outlook with robust profitability metrics like 66.57% net margin and 135.7% ROE offset by negative net cash flow and high debt levels. The consensus price target of $218.45 suggests 10% upside potential, but rising bond yields and $2B in 2024 debt maturities pose headwinds for the retail REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
